8-K: Perrigo Initiates Voluntary Recall of Infant Formula Due to Elevated Vitamin D Levels

Perrigo has voluntarily recalled 16,500 cans of store brand infant formula due to elevated levels of Vitamin D, affecting products sold at H-E-B and CVS.

Summary

• Perrigo has initiated a voluntary recall of three lots within one batch, totaling 16,500 cans, of store brand Premium Infant Formula with Iron Milk-Based Powder.
• The recall is due to elevated levels of Vitamin D above the permitted maximum.
• The affected products were sold at H-E-B Grocery Company and CVS stores.
• Shipments to CVS occurred between February 6-11, 2024, and to H-E-B between February 2, 2024 and May 13, 2024.
• The financial impact of the recall is not expected to be material and does not affect the company's Fiscal Year 2024 outlook.
• The company is working with the FDA on this recall.
• There have been no reports of adverse events related to the elevated Vitamin D levels to date.
• The recall affects specific lot codes: T11LMYC, T11LMXC, and T09LMXC.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative due to the product recall, but the company's proactive response and the immaterial financial impact mitigate the negative aspects.

Positives

• Perrigo initiated the voluntary recall proactively in consultation with the FDA.
• The company has taken immediate action to notify retailers and isolate the affected product.
• The financial impact of the recall is not expected to be material.
• No adverse health events have been reported to date.

Negatives

• The recall involves 16,500 cans of infant formula, which could impact consumer confidence.
• Elevated levels of Vitamin D in the formula could potentially cause health complications in a small subset of vulnerable infants.
• The recall may cause some disruption to retailers and consumers.

Risks

• There is a potential risk of health complications for a small subset of physiologically vulnerable infants.
• The recall could lead to reputational damage for Perrigo.
• There is a risk of future recalls if quality control issues are not addressed.

Future Outlook

The company's Fiscal Year 2024 Outlook remains unchanged despite the recall.

Management Comments

• Perrigo has taken immediate action by notifying H-E-B Grocery Company, LP and CVS directly and asking them to examine their retail and warehouse inventory and isolate the product.

Industry Context

Product recalls in the consumer goods industry are not uncommon, and this recall highlights the importance of stringent quality control measures. The recall is specific to a single batch and does not appear to be indicative of a broader issue with Perrigo's manufacturing processes.

Comparison to Industry Standards

• Other companies in the consumer goods industry, such as Nestle and Abbott, have also faced product recalls due to quality issues.
• The speed and transparency with which Perrigo has handled this recall is comparable to industry best practices.
• The financial impact of the recall is expected to be immaterial, which is typical for recalls of this scale.

Stakeholder Impact

• Shareholders may experience a slight negative impact due to the recall, but the immaterial financial impact should limit the effect.
• Consumers who purchased the affected product are advised to check the lot codes and contact their healthcare provider if they have concerns.
• Retail partners H-E-B and CVS are impacted by the need to remove the recalled product from their shelves.

Next Steps

• Perrigo will continue to work with H-E-B and CVS to remove the affected products from shelves.
• The company will continue to monitor the situation and provide updates as necessary.
• Perrigo will investigate the root cause of the elevated Vitamin D levels to prevent future occurrences.

Key Dates

Keywords

infant formula, voluntary recall, vitamin D, Perrigo, FDA, H-E-B, CVS, product recall, consumer safety